Metabolic Profiles of Individuals Switched to Second-Line Antiretroviral Therapy after Failing Standard First-Line Therapy for Treatment of HIV-1 Infection in a Randomized,Controlled Trial

Noor M.A. , Lo J.C. , Mulligan K. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 2001; 15: F11–F18.

Grunfeld C. Insulin resistance in HIV infection: drugs, host responses, or restoration to health? Top HIV Med 2008; 16: 89–93.

Huisin ‘t Veld D. , Balestre E. , Buyze J. Determinants of weight evolution among HIV-positive patients initiating antiretroviral treatment in low-resource settings. J Acquir Immune Defic Syndr 2015; 70: 146–154.

McComsey G.A. , Moser C. , Currier J. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis 2016; 62: 853–862.

Martin A. , Moore C.L. , Mallon P.W.G. HIV lipodystrophy in participants randomised to lopinavir/ ritonavir (LPV/r) +2–3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy. PLoS One 2013; 8: e77138.

Santos J.R. , Saumoy M. , Curran A. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. Clin Infect Dis 2015; 61: 403–408.

Gallant J.E. , Staszewski S. , Pozniak A.L. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191–201.

Llibre J.M. , Domingo P. , Palacios R. Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir. AIDS 2006; 20: 1407–1414.

Gallant J.E. , DeJesus E. , Arribas J.R. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251–260.

Tungsiripat M. , Kitch D. , Glesby M.J. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010; 24: 1781–1784.

Sax P.E. , Tierney C. , Collier A.C. Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361: 2230–2240.

Moyle G.J. , Stellbrink H.J. , Compston J. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antivir Ther 2013; 18: 905–913.

Martin A. , Amin J. , Cooper D.A. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial. AIDS 2010; 24: 2657–2663.

Lake J.E. , McComsey G.A. , Hulgan T.M. A randomized trial of raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS 2012; 26: 532–540.

Eron J.J. , Young B. , Cooper D.A. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375: 396–407.

Martínez E. , Larrousse M. , Llibre J.M. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010; 24: 1697–1707.

Arribas J.R. , Pialoux G. , Gathe J. Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, Phase 3b, non-inferiority trial. Lancet Infect Dis 2014; 14: 581–589.

Pozniak A. , Markowitz M. , Mills A. Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, Phase 3b non-inferiority trial. Lancet Infect Dis 2014; 14: 590–599.

Molina J-M , Clotet B. , van Lunzen J. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, Phase 3b study. Lancet HIV 2015; 2: e127–e136.

Rockstroh J.K. , DeJesus E. , Henry K. A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF versus ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results. J Acquir Immune Defic Syndr 2013; 62: 483–486.

Hill A. , Sawyer W. , Gazzard B. Effects of first-line use of nucleoside analogues, efavirenz, and ritonavir-boosted protease inhibitors on lipid levels. HIV Clin Trials 2009; 10: 1–12.

Guaraldi G. , Zona S. , Cossarizza A. Switching to darunavir/ritonavir monotherapy vs. triple-therapy on body fat redistribution and bone mass in HIV-infected adults: the Monarch randomized controlled trial. Int J STD AIDS 2014; 25: 207–212.

Chetchotisakd P. The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients. Expert Rev Anti Infect Ther 2009; 7: 801–805.

Molina J-M , Andrade-Villanueva J. , Echevarria J. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646–655.

Mills A.M. , Nelson M. , Jayaweera D. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23: 1679–1688.

Podzamczer D. , Andrade-Villanueva J. , Clotet B. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naive HIV-1-infected patients (the ARTEN study). HIV Med 2011; 12: 374–382.

van Leth F. , Phanuphak P. , Stroes E. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19.

Fätkenheuer G. , Duvivier C. , Rieger A. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother 2012; 67: 685–690.

Katlama C. , Haubrich R. , Lalezari J. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289–2300.

Tebas P. , Sension M. , Arribas J. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1–infected adults treated with rilpivirine or efavirenz for 96 weeks in the ECHO and THRIVE Trials. Clin Infect Dis 2014; 59: 425–434.

Daar E.S. , Tierney C. , Fischl M.A. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial. Ann Intern Med 2011; 154: 445–456.

Erlandson K.M. , Kitch D. , Tierney C. Impact of randomized antiretroviral therapy initiation on glucose metabolism. AIDS 2014; 28: 1451–1461.

WHO. Policy Brief: Consolidated Guidelines on the Use of Antiretroviral Drugs For Treating and Preventing HIV Infection - What's New World Health Organisation. 2015. (Accessed 4 November 2016.) Available from www.who.int/hiv/pub/arv/policy-brief-arv-2015/en/.

Second-Line Study Group, Boyd M.A. , Kumarasamy N. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013; 381: 2091–2099.

Lennox J.L. , DeJesus E. , Berger D.S. Raltegravir versus efavirenz regimens in treatment-naive HIV-1–infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55: 39–48.

Bunupuradah T. , Chetchotisakd P. , Ananworanich J. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ ritonavir in patients failing NNRTI regimens: the HIV STAR study. Antivir Ther 2012; 17: 1351–1361.

Cameron D.W. , da Silva B.A. , Arribas J.R. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 198: 234–240.

Ciaff L. , Koulla-Shiro S. , Sawadogo A. Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa. AIDS 2015; 29: 1473–1481.

Paton N.I. , Kityo C. , Hoppe A. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371: 234–247.

Estill J. , Ford N. , Salazar-Vizcaya L. The need for second-line antiretroviral therapy in adults in sub-Saharan Africa up to 2030: a mathematical modelling study. Lancet HIV 2016; 3: e132–e139.